Ibrahim H, et al. - Researchers focused on the use of glycoprotein IIb/IIIa inhibitors (GPIs) with faster onset, more potent P2Y₁₂ inhibitors. Among 11,781 patients who had percutaneous coronary intervention (PCI) for myocardial infarction (MI), they assessed those who did vs those who did not receive planned GPI for 6-week major adverse cardiac events (MACE: death, recurrent MI, stroke, or unplanned revascularization) and BARC 2+ bleeding events using propensity matching. Overall 4,983 (42.2%) and 229 (4.4%) patients received planned and bailout GPI, respectively. The practicing physicians reported prevalent use of planned GPI between 2010 and 2012. Increased risk of bleeding but not lower MACE was reported in association with planned GPI use.